Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817053 | 0.96 | TSHR (0.71) | TSHRCASP1KMT2AMEN1NPC1 | |
| SCHEMBL2814801 | 0.87 | KMT2A (0.62) | TSHRCASP1KMT2AMEN1NPC1 | |
| SCHEMBL2814975 | 0.84 | KMT2A (0.59) | TSHRCASP1KMT2AMEN1NPC1 | |
| SCHEMBL2815498 | 0.82 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2814692 | 0.81 | KMT2A (0.66) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL10073048 | 0.78 | LMNA (0.77) | TSHRCASP1KMT2AMEN1POLB | |
| SCHEMBL2815432 | 0.76 | KMT2A (0.76) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2817570 | 0.76 | KMT2A (0.76) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2815619 | 0.76 | KMT2A (0.91) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL2814616 | 0.76 | KMT2A (0.76) | KMT2AMEN1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| CN-101679215-A | New benzamide derivatives as the follicle stimulating hormone conditioning agent | ADDEX PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | TSHR 19/4885CASP1 2952/4885KMT2A 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.